Allergy & Asthma Specialists — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$3,172	1
2022	Research	$16,352	4
2021	Research	$90,337	30
2020	Research	$9,780	4
2019	Research	$226,491	26

Breakdown

Who paid Research payments · program years 2019–2023

Shire North American Group Inc $175,421 14 payments
Teva Pharmaceuticals USA, Inc. $170,711 51 payments

Studies the money was for Research payments · program years 2019–2023

Help Study Extensiontm An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Dx-2930 for Prevention Against Acute Attacks of Hereditary Angioedema Hae $175,421 14 payments
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma $64,279 27 payments
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma $51,070 12 payments
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma $48,853 10 payments
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma $6,509 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.